Tags

Type your tag names separated by a space and hit enter

Neurological manifestations of COVID-19: available evidences and a new paradigm.
J Neurovirol. 2020 10; 26(5):619-630.JN

Abstract

The recent pandemic outbreak of coronavirus is pathogenic and a highly transmittable viral infection caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2). In this time of ongoing pandemic, many emerging reports suggested that the SARS-CoV-2 has inimical effects on neurological functions, and even causes serious neurological damage. The neurological symptoms associated with COVID-19 include headache, dizziness, depression, anosmia, encephalitis, stroke, epileptic seizures, and Guillain-Barre syndrome along with many others. The involvement of the CNS may be related with poor prognosis and disease worsening. Here, we review the evidence of nervous system involvement and currently known neurological manifestations in COVID-19 infections caused by SARS-CoV-2. We prioritize the 332 human targets of SARS-CoV-2 according to their association with brain-related disease and identified 73 candidate genes. We prioritize these 73 genes according to their spatio-temporal expression in the different regions of brain and also through evolutionary intolerance analysis. The prioritized genes could be considered potential indicators of COVID-19-associated neurological symptoms and thus act as a possible therapeutic target for the prevention and treatment of CNS manifestations associated with COVID-19 patients.

Authors+Show Affiliations

Amity Institute of Neuropsychology & Neurosciences, Amity University, Noida, Uttar Pradesh, 201303, India.Amity Institute of Neuropsychology & Neurosciences, Amity University, Noida, Uttar Pradesh, 201303, India.Amity Institute of Neuropsychology & Neurosciences, Amity University, Noida, Uttar Pradesh, 201303, India. vkumar33@amity.edu.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32839951

Citation

Khatoon, Fatima, et al. "Neurological Manifestations of COVID-19: Available Evidences and a New Paradigm." Journal of Neurovirology, vol. 26, no. 5, 2020, pp. 619-630.
Khatoon F, Prasad K, Kumar V. Neurological manifestations of COVID-19: available evidences and a new paradigm. J Neurovirol. 2020;26(5):619-630.
Khatoon, F., Prasad, K., & Kumar, V. (2020). Neurological manifestations of COVID-19: available evidences and a new paradigm. Journal of Neurovirology, 26(5), 619-630. https://doi.org/10.1007/s13365-020-00895-4
Khatoon F, Prasad K, Kumar V. Neurological Manifestations of COVID-19: Available Evidences and a New Paradigm. J Neurovirol. 2020;26(5):619-630. PubMed PMID: 32839951.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Neurological manifestations of COVID-19: available evidences and a new paradigm. AU - Khatoon,Fatima, AU - Prasad,Kartikay, AU - Kumar,Vijay, Y1 - 2020/08/24/ PY - 2020/06/16/received PY - 2020/08/14/accepted PY - 2020/07/17/revised PY - 2020/8/26/pubmed PY - 2020/10/21/medline PY - 2020/8/26/entrez KW - COVID-19 KW - Gene enrichment KW - Gene prioritization KW - Neurological damage KW - SARS-CoV-2 SP - 619 EP - 630 JF - Journal of neurovirology JO - J Neurovirol VL - 26 IS - 5 N2 - The recent pandemic outbreak of coronavirus is pathogenic and a highly transmittable viral infection caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2). In this time of ongoing pandemic, many emerging reports suggested that the SARS-CoV-2 has inimical effects on neurological functions, and even causes serious neurological damage. The neurological symptoms associated with COVID-19 include headache, dizziness, depression, anosmia, encephalitis, stroke, epileptic seizures, and Guillain-Barre syndrome along with many others. The involvement of the CNS may be related with poor prognosis and disease worsening. Here, we review the evidence of nervous system involvement and currently known neurological manifestations in COVID-19 infections caused by SARS-CoV-2. We prioritize the 332 human targets of SARS-CoV-2 according to their association with brain-related disease and identified 73 candidate genes. We prioritize these 73 genes according to their spatio-temporal expression in the different regions of brain and also through evolutionary intolerance analysis. The prioritized genes could be considered potential indicators of COVID-19-associated neurological symptoms and thus act as a possible therapeutic target for the prevention and treatment of CNS manifestations associated with COVID-19 patients. SN - 1538-2443 UR - https://www.unboundmedicine.com/medline/citation/32839951/Neurological_manifestations_of_COVID_19:_available_evidences_and_a_new_paradigm_ L2 - https://dx.doi.org/10.1007/s13365-020-00895-4 DB - PRIME DP - Unbound Medicine ER -